Clinical Utility of Cognistat in Multiprofessional Team Evaluations of Patients with Cognitive Impairment in Swedish Primary Care
Table 1
Descriptive data (mean ± standard deviation (SD)) for the cognitive impairment group and the no cognitive impairment group after the final diagnoses.
Variables
Cognitive impairment ()
No cognitive impairment ()
value
Females/males
22/24
25/8
0.013
Age, years ± SD
0.004
Education, years ± SD
0.037
Native language, (%)
Swedish
42 (91)
33 (100)
Non-Swedish
4 (9)
0 (0)
Duration of cognitive symptoms, years ± SD
<0.001
Range
1–9
0–4
Medical history, (%)
Cerebrovascular disease
5 (11)
1 (3)
Ischemic heart disease
15 (33)
5 (15)
0.078
Hypertension
30 (65)
17 (52)
0.221
Diabetic disease
7 (15)
1 (3)
Anxiety
4 (9)
0 (0)
Mild depression
6 (13)
1 (3)
Medical drugs, (%)
Warfarin
7 (15)
4 (12)
Salicylic acid (low dose)
25 (54)
10 (30)
0.034
Lipid-lowering drug
25 (54)
10 (30)
0.034
Antihypertensive
38 (83)
18 (54)
0.007
Insulin
4 (9)
0 (0)
Antidiabetic
3 (7)
1 (3)
Antidepressant
18 (39)
7 (21)
0.091
Sleeping drug
16 (35)
5 (15)
0.051
Antipsychotic
4 (9)
0 (0)
Anxiolytic
11 (24)
4 (12)
0.188
value analysed by -test for age, education, and duration of symptoms. Chi-square and Fisher exact test for native language, medical history, and medical drugs. Significant value <0.05.